CompletedNCT00505765
NAP for cognitive difficulties in schizophrenia
About this title
Read the official source — NCT00505765Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Los Angeles and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 63
- Sponsor
- University of California, Los Angeles
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00505765
- Official title
Show the full official title
A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles · Catonsville · Boston
4 more locations
- St Louis
- New York
- Orangeburg
- Durham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, Los Angeles, a university.
Did this study involve medication?
Yes. The study involved medication, including AL-108 and Placebo.
Who was this study for?
Listed age limits: 18 years to 60 years.
